Intravitreal bevacizumab plus propranolol for neovascular age-related macular degeneration (the BEVALOL study): a phase I clinical trial

Keyphrases

• Intravitreal Bevacizumab 100%
• Propranolol 100%
• Phase I Clinical Trial 100%
• Neovascular Age-related Macular Degeneration (nAMD) 100%
• Bevacizumab 60%
• Full-field Electroretinography 60%
• Beta-blockers 40%
• Optical Coherence Tomography 40%
• Fluorescein Angiography 40%
• Best-corrected Visual Acuity 40%
• Intravitreal Injection 40%
• Anti-VEGF Therapy 40%
• Color Fundus Photography 40%
• Combination Therapy 20%
• Intravitreal 20%
• Adverse Events 20%
• Synergistic Effect 20%
• Brazil 20%
• Early Treatment Diabetic Retinopathy Study 20%
• Clinical Evaluation 20%
• Spectral Domain Optical Coherence Tomography (SD-OCT) 20%
• Cost Reduction 20%
• Therapeutic Potential 20%
• Endophthalmitis 20%
• Anterior Segment 20%
• Public Health Impact 20%
• Trial Registration 20%
• Optical Coherence Tomography Angiography (OCT-A) 20%
• Intraocular Pressure Elevation 20%
• Central Subfield Thickness 20%
• Ethics Committees 20%
• Neovascularization 20%
• Study Evaluation 20%
• Heidelberg 20%
• Ocular Inflammation 20%
• B-wave 20%
• Posterior Segment 20%
• Ocular Toxicity 20%
• Baseline Evaluation 20%
• Biomicroscopy 20%
• Spectralis 20%
• Brasil 20%

Medicine and Dentistry

• Clinical Trial 100%
• Bevacizumab 100%
• Propranolol 100%
• Wet Macular Degeneration 100%
• Optical Coherence Tomography 60%
• Electroretinography 60%
• Fluorescein Angiography 40%
• Fundus Photography 40%
• Best Corrected Visual Acuity 40%
• Intravitreal Administration 40%
• Vasculotropin 40%
• Medicine 20%
• Health Care Cost 20%
• Combination Therapy 20%
• Intraocular Pressure 20%
• Adverse Event 20%
• Public Health 20%
• Agents Acting on the Eye 20%
• Diabetic Retinopathy 20%
• Endophthalmitis 20%
• Ophthalmoscopy 20%
• Beta Adrenergic Receptor Blocking Agent 20%
• Evaluation Study 20%
• Ultrasound Biomicroscopy 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Clinical Trial 100%
• Bevacizumab 100%
• Propranolol 100%
• Wet Macular Degeneration 100%
• Vasculotropin 40%
• Intravitreal Administration 40%
• Fluorescein 40%
• Adverse Event 20%
• Inflammation 20%
• Combination Therapy 20%
• Agents Acting on the Eye 20%
• Diabetic Retinopathy 20%
• Endophthalmitis 20%
• Beta Adrenergic Receptor Blocking Agent 20%
• Neovascularization (Pathology) 20%